1. Brigatinib in crizotinib-refractory ALK+ non-small cell lung cancer (NSCLC): efficacy updates and exploratory analysis of target lesion response by baseline brain lesion status in the ALTA Trial. (January 2019) Authors: Kim, D.; Huber, R.; Ahn, M.; Langer, C.; Tiseo, M.; West, H.; Groen, H.; Reckamp, K.; Hochmair, M.; Leighl, N.; Hansen, K.H.; Gettinger, S.; Paz-Ares Rodriguez, L.; Kim, E.; Smit, E.; Kim, S.; Reichmann, W.; Kerstein, D.; Camidge, D.R. Journal: Lung cancer Issue: Volume 127(2019)Supplement 1 Page Start: S30 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗